The tweet was deleted by the author.
But we saved everything 🙂.
UroGen Pharma said Jason guides the company through an evolving regulatory landscape and helps foster a culture of integrity and accountability.
The company noted Jason's deep experience in healthcare, pharmaceutical, and corporate law. Further information about UroGen Pharma's leadership is available through its posted link.
View post on X Loading...
URGN is trading at $34.88, well above the MA-20 ($30.45), MA-50 ($28.17), and MA-200 ($22.48), which confirms a strong bullish structure for short-, medium-, and long-term trends. The Ichimoku Kijun on D1 sits at $31.04, marking immediate support below the current price. Near-term support is clustered around the Ichimoku Kijun ($31.04), with key support at MA-50 ($28.17). Near-term resistance is located at the MA-5 cluster ($34.90), while key resistance aligns with the recent 52-week high ($36.08).
Momentum indicators on D1 are decisively positive, with both MACD and ADX showing strong upward momentum. RSI has reached 70.28 and CCI reads 94.93, both indicating stretched but not extreme overbought territory. Stoch RSI is neutral at 73.83, while BBP is clearly in overbought territory at 2.37, highlighting persistent buyer dominance in intraday action. The Awesome Oscillator is in alignment with the bullish trend. URGN is trading at $34.88, up from last week’s close at $34.54, marking a 1.13% gain. Price action is positioned in the middle of the weekly range between $33.80 and $36.08, with weekly volatility standing at 6.75%. The weekly tone reflects consolidation after reaching a 52-week high.
For the coming week, the expected price range is $33.50 to $36.00, normalized for recent volatility and anchored well above the 52-week low ($12.73) yet within the orbit of the 52-week high ($36.08). Based on the alignment of W1 indicators (strong Buy signals from RSI-W1, ADX-W1, MACD-W1, and MA-50-W1), there is a very high probability (more than 80%) of upward movement, making a downward move less likely. Baseline scenario calls for a sideways pattern as the price consolidates between $33.50 and $36.00. Bullish scenario sees a break above $36.00, targeting new highs. Bearish scenario would require a breakdown below support at $31.04, exposing the $28.17 area as the next downside test.
Earlier, analysts noted that UroGen Pharma was exhibiting a bullish bias in medium-term trends despite facing short-term resistance and signals of consolidation. The current article adds a new dimension by highlighting evolving catalysts and encourages investors to monitor for signs of a breakout or a shift toward renewed momentum in trading.